


2022 Novel Large Molecule Drug Approvals


Oncology (6)



Elahere | FR α -binding maytansinoid ADC
(mirvetuximab soravtansine-gynx)
for ovarian cancer resistant to platinum
6 mg/kg IV infusion Q3W
IMMUNOGEN




Kimmtrak | bispecific gp100 peptide-HLA-directed CD3 T cell engager
(tebentafusp-tebn)
for uveal melanoma
starting dose 20 μ g IV infusion
IMMUNOCORE



Opdivo | Lag-3 checkpoint inhibitor
(nivolumab (PD-1) and relatlimab-rmbw*)
for melanoma
480 mg nivolumab and 160 mg relatlimab IV infusion Q4W
BMS



Tecvayli | BCMA-directed CD3 T-cell engager
(teclistamab-cqyv)
for R/R MM
starting dose 0.06 mg/kg SC
JANSSEN



Lunsumio | CD20xCD3 T-cell engager
(mosunetuzumab-axgb)
for R/R follicular lymphoma
starting dose 1 mg IV infusion
ROCHE




Imjudo | CTLA-4 checkpoint inhibitor
(tremelimumab)
for hepatocellular carcinoma
300 mg IV tremelimumab Q4W w/ durvalumab
ASTRAZENECA


Hematology/Oncology (1)

Hematology (1)


Ophthalmology (1)



Rolvedon | rhG-CSF
(eflapegastim)
for infection related to neutropenia in cancer
13.2 mg SC once per chemotherapy cycle
SPECTRUM PHARMACEUTICALS




Enjaymo | complement component (C1s) inhibitor
(sutimlimab-jome)
for cold agglutinin disease
starting dose 6.5 g IV infusion QW
SANOFI




Vabysmo | VEGF and Ang-2 inhibitor
(faricimab-svoa)
for neovascular AMD and diabetic macular edema
6 mg intravitreally Q4W
GENENTECH

Rare Disease (1)


Neurology (2)



Xenpozyme | acid sphingomyelinase replacement
(olipudase alfa)
for Acid Sphingomyelinase Deficiency
starting dose 0.1 mg/kg IV infusion
SANOFI




Amvuttra | TTR siRNA
(vutrisiran)
for polyneuropathy of hereditary transthyretin-mediated amyloidosis
25 mg SC Q3M
ALNYLAM PHARMACEUTICALS




Briumvi | anti-CD20 mAb
(ublituximab-xiyl)
for relapsed MS
starting dose 150 mg IV infusion
TG THERAPEUTICS


Dermatology (3)



Spevigo | IL-36 receptor antagonist
(spesolimab-sbzo)
for psoriasis symptoms
single dose: 450 mg/7.5 mL solution IV
BOEHRINGER INGELHEIM




Daxxify | ACh release inhibitor (botulinum toxin formulation)
(daxibotulinumtoxinA-lanm)
for moderate to severe glabellar lines
0.1 mL IM into five sites
REVANCE THERAPEUTICS




Nexobrid | proteolytic enzymes enriched in bromelain
(anacaulase-bcdb)
for removing eschar caused by thermal burns
2 g per 1% total body surface area
MEDIWOUND

Endocrinology (2)



Mounjaro | GIP and GLP-1 receptor agonist
(tirzepatide)
for diabetes
2.5 mg SC QW
ELI LILLY



Tzield | CD3-directed immunosuppressant
(teplizumab-mzwv)
to delay the onset of Stage 3 Type 1 diabetes
IV infusion QD over 14 d
PROVENTION BIO/SANOFI



visit for more information on <https://drughunters.com/3GqtJMZ>
each drug including:
• how they were discovered
• how they work
• how they differentiate
• ...and more